L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile

The newly developed Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) has consistently been shown to be prognostically significant in endometrial carcinomas (EC). Recently, we and others have demonstrated L1 cell-adhesion molecule (L1CAM) to be a significant indicator of high-risk...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 2018-08, Vol.119 (4), p.480-486
Main Authors: Kommoss, Felix Kf, Karnezis, Anthony N, Kommoss, Friedrich, Talhouk, Aline, Taran, Florin-Andrei, Staebler, Annette, Gilks, C Blake, Huntsman, David G, Krämer, Bernhard, Brucker, Sara Y, McAlpine, Jessica N, Kommoss, Stefan
Format: Article
Language:English
Subjects:
Carcinoma
Endometrial cancer
Endometrium
Health risks
Immunohistochemistry
Multivariate analysis
p53 Protein
Tumors
Uterine cancer
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The newly developed Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) has consistently been shown to be prognostically significant in endometrial carcinomas (EC). Recently, we and others have demonstrated L1 cell-adhesion molecule (L1CAM) to be a significant indicator of high-risk disease in EC. In the current study, it was our aim to determine the prognostic significance of aberrant L1CAM expression in ProMisE subgroups in a large, single centre, population-based EC cohort. ProMisE (POLE; MMR-D; p53 wt/NSMP; p53 abn) classification results from a cohort of 452 EC were available for analysis. L1CAM expression was studied by immunohistochemistry on whole slides. Correlations between clinicopathological data and survival were calculated. Expression of L1CAM was most frequent in p53 abnormal tumours (80%). L1CAM status was predictive of worse outcome among tumours with no specific molecular profile (p53 wt/NSMP) (p 
ISSN:0007-0920
1532-1827
DOI:10.1038/s41416-018-0187-6